Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04554940 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Clinical Trial to Evaluate Safety of Vosoritide in At-risk Infants With Achondroplasia

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. 5 versions Re-verified since Aug 1, 2023, no change to tracked fieldsv9-v13
  2. Primary and study completion dates: Dec 2026 to Dec 2027v8
  3. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 3 of 3 sites
    v7
  4. Site details revised at 1 of 3 sitesv6
  5. Site details revised at 1 of 3 sitesv5
Show 3 earlier versionsHide 3 earlier versions
  1. Study sites: 2 to 3v4
  2. Start date changed from estimate of Sep 2020 to Oct 10, 2020v3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Site details revised at 2 of 2 sites
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Study 111-209 is a Phase 2 randomized, open-label clinical trial of BMN 111 in infants and young children with a diagnosis of Achondroplasia at a heightened risk of requiring cervicomedullary decompression surgery
Trial Details
NCT Number NCT04554940
Lead Sponsor BioMarin Pharmaceutical
Conditions
(from sponsor)		 Achondroplasia
Related terms Achondroplasia, Bone Diseases, Dwarfism, Musculoskeletal Diseases
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov